Bio-Path Holdings logo
Bio-Path Holdings BPTH
report update icon

Quarterly report 2026-Q1
added 05-20-2026

Bio-Path Holdings Financial Statements 2024-2007 | BPTH

Annual Financial Statements Bio-Path Holdings

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Market Cap

7.76 M 2.94 M 575 K 25.2 M 15.3 M 17 M 1.21 M 23.2 M 86.2 M 126 M 202 M 311 M 20.2 M 13.5 M 90.9 B - - -

Shares

2.4 M 478 K 364 K 6.72 M 3.69 M 2.66 M 597 K 504 K 464 K 449 K 446 K 357 K 297 K 269 K 49.4 M - - -

Historical Prices

3.23 6.15 1.58 3.75 6.48 5.48 2.6 33.8 164 356 370 838 70 68 1.84 K 1.24 K 16 K -

Net Income

-9.89 M -16.1 M -13.9 M -10.4 M -10.9 M -8.6 M -8.58 M -7.02 M -6.75 M -5.47 M -4.52 M -3.27 M -2.58 M -2.36 M -2.08 M -433 K -1.89 M -143 K

Revenue

- - - - - - - 37 K 13 K - - - - - - - - -

Operating Income

-12 M -15.8 M -13.9 M -10.4 M -10.9 M -8.69 M -8.59 M -8.97 M -8.48 M -5.48 M -4.54 M -3.27 M -2.58 M -2.37 M -2.33 M - - -

EBITDA

-11.9 M -15.8 M -13.8 M -10.4 M -10.8 M -8.46 M -7.56 M -8.56 M -8.27 M -5.28 M -4.37 M -3.11 M -2.4 M -2.15 M -2.33 M - - -

Operating Expenses

12 M 15.8 M 13.9 M 10.4 M 10.9 M 8.69 M 7.98 M 9 M 8.49 M 5.48 M 4.54 M 3.27 M 2.58 M 2.37 M 2.33 M - - -

General and Administrative Expenses

4.7 M 4.24 M 4.74 M 4.53 M 4.33 M 4.11 M 3.38 M 3.52 M 3.01 M 2.46 M 2.72 M 1.63 M 986 K - 1.13 M - - -

All numbers in USD currency

Quarterly Income Statement Bio-Path Holdings

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

9.34 M 9.24 M 8.31 M 7.06 M 5.77 M 3.02 M 1.61 M 647 K 618 K 503 K 398 K 398 K 7.96 M 7.16 M 7.16 M 7.16 M 7.16 M 7.04 M 6.96 M 5.72 M 4.54 M 3.69 K 3.69 K 3.69 M 3.69 M 2.87 M 2.83 M 1.7 M 680 K 573 K 567 K 567 K 567 10 M 9.86 M 9.56 M 9.56 K 95.6 M 89.8 M 89.8 M 89.8 M 89.8 K 89.8 K 89.8 K 89.8 M 89.2 M 89.2 M 89.2 M 84.2 M 75.4 M 66.6 M 62.2 M 62.2 M 58.9 M 58.9 M 58.4 M 58.3 M 56.1 M 51.6 M 58.3 M

Net Income

-270 K -976 K -4.6 M -2.85 M - -2.12 M -1.87 M -3.16 M - -3.2 M -4.23 M -5.27 M - -3.54 M -3.01 M -3.36 M - -2.07 M -1.81 M -2.45 M - -2.97 M -2.04 M -3.32 M - -2.24 M -2.46 M -1.51 M - -3.08 M -1.68 M -1.92 M - -2.47 M -1.98 M -397 K -1.37 M -1.57 M -1.94 M -1.87 M -1.46 M -1.51 M -1.13 M -1.38 M -1.6 M -1.15 M -1.27 M -505 K -790 K -1.39 M -427 K -656 K - -841 K -788 K -522 K - -504 K -463 K -593 K

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 13 K - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-297 K -488 K -4.56 M -3.24 M - -2.63 M -3.04 M -3.7 M - -3.28 M -4.24 M -5.29 M - -3.55 M -3.01 M -3.36 M - -2.07 M -1.81 M -2.45 M - -2.97 M -2.04 M -3.34 M - -2.27 M -2.49 M -1.52 M - -3.08 M -1.68 M -1.92 M - -2.48 M -2.32 M -2 M -1.67 M -2.99 M -1.94 M -1.87 M -1.46 M -1.51 M -1.13 M -1.38 M -1.6 M -1.15 M -1.27 M -510 K -791 K -1.39 M -429 K -656 K - -840 K -788 K -523 K - -504 K -464 K -593 K

EBITDA

-295 K - - -3.24 M - - -3.01 M -3.67 M - - - -5.27 M - -3.48 M -2.97 M -3.34 M - -2.01 M -1.77 M -2.43 M - -2.92 M -2.01 M -3.33 M - -2.16 M -2.39 M -1.45 M - -2.88 M -1.55 M -1.85 M - -2.29 M -2.22 M -1.96 M -1.67 M -2.96 M -1.92 M -1.86 M -1.46 M -1.48 M -1.11 M -1.37 M -1.6 M -1.15 M -1.27 M -510 K -791 K -1.39 M -429 K -656 K - -840 K -788 K -523 K - -504 K -464 K -593 K

Operating Expenses

297 K 488 K 4.56 M 3.24 M - 2.63 M 3.04 M 3.7 M - 3.28 M 4.24 M 5.29 M - 3.55 M 3.01 M 3.36 M - 2.07 M 1.81 M 2.45 M - 2.97 M 2.04 M 3.34 M - 2.27 M 2.49 M 1.52 M - 3.08 M 1.68 M 1.92 M - 2.48 M 2.32 M 2 M 1.68 M 2.99 M 1.94 M 1.87 M 1.46 M 1.51 M 1.13 M 1.38 M 1.6 M 1.15 M 1.27 M 510 K 791 K 1.39 M 429 K 656 K - 840 K 788 K 523 K - 504 K 464 K 593 K

General and Administrative Expenses

259 K 213 K 514 K 1.26 M - 1.32 M 1.16 M 1.41 M - 984 K 1.19 M 1.3 M - 1.19 M 1.16 M 1.26 M - 1.09 M 1.05 M 1.19 M - 970 K 1.01 M 1.34 M - 896 K 966 K 1.12 M - 740 K 852 K 987 K - 893 K 845 K 970 K - 681 K 757 K 849 K - 520 K 567 K 786 K - 713 K 755 K 381 K - 810 K 241 K 240 K - 246 K 252 K 231 K - 327 K 325 K 350 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Bio-Path Holdings BPTH
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Bio-Path Holdings plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Assembly Biosciences Assembly Biosciences
ASMB
$ 23.49 0.04 % $ 263 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 227.83 0.5 % $ 13.8 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.65 1.09 % $ 23.3 B australiaAustralia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.12 0.88 % $ 34.9 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 1.95 1.51 % $ 16.8 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 8.5 5.59 % $ 107 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.2 0.49 % $ 2.18 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.94 4.3 % $ 516 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 5.21 0.58 % $ 425 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 2.02 0.43 % $ 172 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 422.52 0.7 % $ 33 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 184.39 0.73 % $ 9.17 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.14 1.38 % $ 26.4 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 65.8 0.34 % $ 12.6 B usaUSA
BioCardia BioCardia
BCDA
$ 1.01 0.96 % $ 6.73 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 8.33 0.73 % $ 1.75 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.68 0.82 % $ 255 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.89 0.8 % $ 107 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 24.45 0.37 % $ 2.42 B usaUSA
Biogen Biogen
BIIB
$ 225.88 0.15 % $ 33.1 B usaUSA
BioVie BioVie
BIVI
$ 1.52 1.95 % $ 2.25 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.32 2.67 % $ 5.72 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.0 0.22 % $ 11.5 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.4 0.19 % $ 127 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.0 2.56 % $ 466 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 98.3 0.02 % $ 23.8 B germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 3.92 0.51 % $ 859 M britainBritain
BeyondSpring BeyondSpring
BYSI
$ 0.77 2.15 % $ 31.7 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 1.92 0.75 % $ 193 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.2 0.92 % $ 3.62 M israelIsrael
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 9.47 10.5 % $ 440 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.59 1.58 % $ 1.3 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.33 6.39 % $ 276 M usaUSA
Codexis Codexis
CDXS
$ 1.39 2.96 % $ 121 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.38 0.82 % $ 454 M usaUSA
Certara Certara
CERT
$ 9.2 0.11 % $ 1.48 B usaUSA
Cullinan Management Cullinan Management
CGEM
$ 15.35 0.79 % $ 925 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.38 1.28 % $ 222 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.21 2.54 % $ 142 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.41 2.43 % $ 2.15 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.78 0.13 % $ 46.1 M israelIsrael
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.51 2.72 % $ 151 M franceFrance
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.84 1.1 % $ 4.8 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 5.3 8.0 % $ 2.35 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.15 2.68 % $ 13 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 21.82 0.44 % $ 691 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 115.23 0.43 % $ 12 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 6.82 2.87 % $ 90.8 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.21 3.42 % $ 80.9 M usaUSA
Curis Curis
CRIS
$ 0.84 1.21 % $ 11.1 M usaUSA